Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
As in the LEAN study, the primary outcome is histologic resolution of NASH without worsening of fibrosis after 72 weeks of treatment, while secondary outcomes include improvement in liver fibrosis (1 stage) with no worsening of NASH, NAFLD activity score, as well as multiple serum markers of fibrosis
Currently, only two GLP-1 medications are FDA-approved for weight loss in adolescents and children: liraglutide and semaglutide
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
Furthermore, its extended activity makes it a valuable option for athletes and researchers focused on performance and recovery
US$ 26.50
US$ 24.99
US$ 27.50
US$ 27.53
US$ 22.71
